IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs
NCT ID: NCT00128518
Last Updated: 2025-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
139 participants
INTERVENTIONAL
2004-10-31
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
These factors can be of different types:
* Environmental factors (sodium or alcohol intake);
* Morphological (height, weight, body mass index, body surface area);
* Initial blood pressure;
* Electrocardiogram (ECG) parameters of left ventricular hypertrophy;
* Biological parameters as the activity level of the renin angiotensin aldosterone system;
* Genetic polymorphisms.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A : T1+P2 ● P1+P2 ● T2+P1 ● P1+P2
T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
Indapamide (T2)
1.5 mg/day during 4 weeks
Perindopril (T1)
4 mg/day during 1 week then 8 mg/day during 3 weeks
Placebo of Perindopril (P1)
1 pill/day during 1 week then 2 pills/day during 3 weeks
Placebo of Indapamide (P2)
1 pill/day during 4 weeks
Group B : P1+P2 ● T1+P2 ● P1+P2 ● T2+P1
T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
Indapamide (T2)
1.5 mg/day during 4 weeks
Perindopril (T1)
4 mg/day during 1 week then 8 mg/day during 3 weeks
Placebo of Perindopril (P1)
1 pill/day during 1 week then 2 pills/day during 3 weeks
Placebo of Indapamide (P2)
1 pill/day during 4 weeks
Group C : T2+P1 ● P1+P2 ● T1+P2 ● P1+P2
T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
Indapamide (T2)
1.5 mg/day during 4 weeks
Perindopril (T1)
4 mg/day during 1 week then 8 mg/day during 3 weeks
Placebo of Perindopril (P1)
1 pill/day during 1 week then 2 pills/day during 3 weeks
Placebo of Indapamide (P2)
1 pill/day during 4 weeks
Group D : P1+P2 ● T2+P1 ● P1+P2 ● T1+P2
T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
Indapamide (T2)
1.5 mg/day during 4 weeks
Perindopril (T1)
4 mg/day during 1 week then 8 mg/day during 3 weeks
Placebo of Perindopril (P1)
1 pill/day during 1 week then 2 pills/day during 3 weeks
Placebo of Indapamide (P2)
1 pill/day during 4 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Indapamide (T2)
1.5 mg/day during 4 weeks
Perindopril (T1)
4 mg/day during 1 week then 8 mg/day during 3 weeks
Placebo of Perindopril (P1)
1 pill/day during 1 week then 2 pills/day during 3 weeks
Placebo of Indapamide (P2)
1 pill/day during 4 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both genders
* Systolic blood pressure of 140 mmHg or above; diastolic blood pressure of 90 mmHg or above.
* Cardiovascular risk must not be high, to allow for two periods of 4 weeks of placebo without ethical concern.
25 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francois GUEYFFIER, MD
Role: PRINCIPAL_INVESTIGATOR
Hospices Civils de Lyon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Louis Pradel
Bron, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gueyffier F, Subtil F, Bejan-Angoulvant T, Zerbib Y, Baguet JP, Boivin JM, Mercier A, Leftheriotis G, Gagnol JP, Fauvel JP, Giraud C, Bricca G, Maucort-Boulch D, Erpeldinger S; IDEAL Trial Group. Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial. J Hum Hypertens. 2015 Jan;29(1):22-7. doi: 10.1038/jhh.2014.29. Epub 2014 Apr 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2003.340
Identifier Type: -
Identifier Source: org_study_id